Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

904 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study.
Gupta M, Martineau P, Tran T, Després JP, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Blanco-Colio LM, Egido J, Langer A; ACTFAST investigators. Gupta M, et al. Among authors: gensini gf. J Clin Pharmacol. 2012 Jun;52(6):850-8. doi: 10.1177/0091270011407196. Epub 2011 May 24. J Clin Pharmacol. 2012. PMID: 21610204 Clinical Trial.
Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Martineau P, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Langer A; ACTFAST investigators. Martineau P, et al. Among authors: gensini gf. Atherosclerosis. 2007 Mar;191(1):135-46. doi: 10.1016/j.atherosclerosis.2006.03.019. Epub 2006 Apr 27. Atherosclerosis. 2007. PMID: 16643923 Clinical Trial.
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Hérnandez G, Egido J; ACTFAST investigators. Blanco-Colio LM, et al. Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):168-74. doi: 10.1161/01.ATV.0000250616.26308.d7. Epub 2006 Oct 19. Arterioscler Thromb Vasc Biol. 2007. PMID: 17053166 Free article. Clinical Trial.
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J; ACTFAST investigators. Blanco-Colio LM, et al. Am Heart J. 2007 May;153(5):881-8. doi: 10.1016/j.ahj.2007.02.029. Am Heart J. 2007. PMID: 17452168 Clinical Trial.
Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.
Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J; ACTFAST investigators. Blanco-Colio LM, et al. Kidney Int Suppl. 2008 Dec;(111):S60-3. doi: 10.1038/ki.2008.514. Kidney Int Suppl. 2008. PMID: 19034329 Free article. Clinical Trial.
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Richard Hobbs FD, Gensini G, John Mancini GB, Manolis AJ, Bauer B, Genest J, Feldman RD, Harvey P, Jenssen TG, da Silva PM; JEWEL Study Group. Richard Hobbs FD, et al. Eur J Cardiovasc Prev Rehabil. 2009 Aug;16(4):472-80. doi: 10.1097/HJR.0b013e32832b63f5. Eur J Cardiovasc Prev Rehabil. 2009. PMID: 19407658 Clinical Trial.
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program).
Hobbs FD, Gensini G, Mancini GB, Manolis AJ, Bauer B, Böhler S, Genest J, Feldman R, Harvey P, Jenssen TG, Metcalfe M, da Silva PM; JEWEL Study Group. Hobbs FD, et al. Int J Cardiol. 2006 Jun 16;110(2):242-50. doi: 10.1016/j.ijcard.2005.10.017. Epub 2005 Dec 9. Int J Cardiol. 2006. PMID: 16338012
AIHEMAF-P: An Innovative Healthcare Model for Atrial Fibrillation Patients.
La Regina R, Innelli P, Glisenti F, Bollani G, Leopardi E, Gensini GF, Nodari S, La Regina G, La Regina M, Gabbrielli F. La Regina R, et al. Among authors: gensini gf. Pharmacy (Basel). 2024 Dec 15;12(6):187. doi: 10.3390/pharmacy12060187. Pharmacy (Basel). 2024. PMID: 39728852 Free PMC article.
904 results